Replies to post #353115 on Option Millionaires

[jimmybob]

Biogen raises FY22 adjusted EPS view to $15.25-$16.75, consensus $15.54
Previous view was $14.25-$16.00. Raises FY22 revenue view to $9.9B-$10.1B from $9.7B-$10B, consensus $9.84B. The increase in full year 2022 revenue and Non-GAAP diluted EPS guidance is driven primarily by better-than-expected topline performance and continued cost management. This guidance assumes continued declines in RITUXAN revenue due to biosimilar competition, as well as continued erosion of TECFIDERA revenue in the U.S. due to generic entry